ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

NCT01009788 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Metastatic Breast Cancer
BRCA1 Gene Mutation
brca2 Gene Mutation

Interventions

DRUG: ABT-888
DRUG: temozolomide

Sponsor

Steven J Isakoff, MD, PhD

Collaborators

[object Object]
[object Object]
[object Object]